Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 137

1.

Immune regulatory activities of early secreted antigenic target of 6-kD protein of Mycobacterium tuberculosis and implications for tuberculosis vaccine design.

Samten B, Wang X, Barnes PF.

Tuberculosis (Edinb). 2011 Dec;91 Suppl 1:S114-8. doi: 10.1016/j.tube.2011.10.020. Epub 2011 Dec 9. Review.

2.

Novel lipopeptides of ESAT-6 induce strong protective immunity against Mycobacterium tuberculosis: Routes of immunization and TLR agonists critically impact vaccine's efficacy.

Gupta N, Vedi S, Kunimoto DY, Agrawal B, Kumar R.

Vaccine. 2016 Nov 4;34(46):5677-5688. doi: 10.1016/j.vaccine.2016.08.075. Epub 2016 Sep 29.

PMID:
27693020
3.

Mycobacterium tuberculosis ESX-1 system-secreted protein ESAT-6 but not CFP10 inhibits human T-cell immune responses.

Samten B, Wang X, Barnes PF.

Tuberculosis (Edinb). 2009 Dec;89 Suppl 1:S74-6. doi: 10.1016/S1472-9792(09)70017-4.

PMID:
20006311
4.

Recombinant DNA vaccine of the early secreted antigen ESAT-6 by Mycobacterium tuberculosis and Flt3 ligand enhanced the cell-mediated immunity in mice.

Xu J, Xu W, Chen X, Zhao D, Wang Y.

Vaccine. 2008 Aug 18;26(35):4519-25. doi: 10.1016/j.vaccine.2008.06.044. Epub 2008 Jul 1.

PMID:
18598729
5.

Improved cellular immune response elicited by a ubiquitin-fused ESAT-6 DNA vaccine against Mycobacterium tuberculosis.

Wang QM, Kang L, Wang XH.

Microbiol Immunol. 2009 Jul;53(7):384-90. doi: 10.1111/j.1348-0421.2009.00138.x.

6.

Hepatitis B virus core particles displaying Mycobacterium tuberculosis antigen ESAT-6 enhance ESAT-6-specific immune responses.

Yin Y, Li H, Wu S, Dong D, Zhang J, Fu L, Xu J, Chen W.

Vaccine. 2011 Aug 5;29(34):5645-51. doi: 10.1016/j.vaccine.2011.06.012. Epub 2011 Jun 29.

PMID:
21689705
7.

Cloning, expression, and immunogenicity of novel fusion protein of Mycobacterium tuberculosis based on ESAT-6 and truncated C-terminal fragment of HSP70.

Tebianian M, Hoseini AZ, Ebrahimi SM, Memarnejadian A, Mokarram AR, Mahdavi M, Sohrabi N, Taghizadeh M.

Biologicals. 2011 May;39(3):143-8. doi: 10.1016/j.biologicals.2011.02.002. Epub 2011 Mar 8.

PMID:
21388826
8.

Immunogenic potential of latency associated antigens against Mycobacterium tuberculosis.

Singh S, Saraav I, Sharma S.

Vaccine. 2014 Feb 3;32(6):712-6. doi: 10.1016/j.vaccine.2013.11.065. Epub 2013 Dec 2. Review.

PMID:
24300592
9.

Tuberculosis subunit vaccination provides long-term protective immunity characterized by multifunctional CD4 memory T cells.

Lindenstrøm T, Agger EM, Korsholm KS, Darrah PA, Aagaard C, Seder RA, Rosenkrands I, Andersen P.

J Immunol. 2009 Jun 15;182(12):8047-55. doi: 10.4049/jimmunol.0801592.

10.

Chimaeric protein improved immunogenicity compared with fusion protein of Ag85B and ESAT-6 antigens of Mycobacterium tuberculosis.

Xu Y, Wang B, Chen J, Wang Q, Zhu B, Shen H, Qie Y, Wang J, Wang H.

Scand J Immunol. 2006 Nov;64(5):476-81.

11.

Enhanced protection against tuberculosis by vaccination with recombinant Mycobacterium microti vaccine that induces T cell immunity against region of difference 1 antigens.

Brodin P, Majlessi L, Brosch R, Smith D, Bancroft G, Clark S, Williams A, Leclerc C, Cole ST.

J Infect Dis. 2004 Jul 1;190(1):115-22. Epub 2004 Jun 4.

PMID:
15195250
12.

Rv3615c is a highly immunodominant RD1 (Region of Difference 1)-dependent secreted antigen specific for Mycobacterium tuberculosis infection.

Millington KA, Fortune SM, Low J, Garces A, Hingley-Wilson SM, Wickremasinghe M, Kon OM, Lalvani A.

Proc Natl Acad Sci U S A. 2011 Apr 5;108(14):5730-5. doi: 10.1073/pnas.1015153108. Epub 2011 Mar 22.

13.

Bacterial polyester inclusions engineered to display vaccine candidate antigens for use as a novel class of safe and efficient vaccine delivery agents.

Parlane NA, Wedlock DN, Buddle BM, Rehm BH.

Appl Environ Microbiol. 2009 Dec;75(24):7739-44. doi: 10.1128/AEM.01965-09. Epub 2009 Oct 16.

14.
15.

Alteration of epitope recognition pattern in Ag85B and ESAT-6 has a profound influence on vaccine-induced protection against Mycobacterium tuberculosis.

Bennekov T, Dietrich J, Rosenkrands I, Stryhn A, Doherty TM, Andersen P.

Eur J Immunol. 2006 Dec;36(12):3346-55.

16.

Live attenuated Salmonella vaccines against Mycobacterium tuberculosis with antigen delivery via the type III secretion system.

Juárez-Rodríguez MD, Arteaga-Cortés LT, Kader R, Curtiss R 3rd, Clark-Curtiss JE.

Infect Immun. 2012 Feb;80(2):798-814. doi: 10.1128/IAI.05525-11. Epub 2011 Dec 5.

17.

Vaccine potential of influenza vectors expressing Mycobacterium tuberculosis ESAT-6 protein.

Stukova MA, Sereinig S, Zabolotnyh NV, Ferko B, Kittel C, Romanova J, Vinogradova TI, Katinger H, Kiselev OI, Egorov A.

Tuberculosis (Edinb). 2006 May-Jul;86(3-4):236-46.

PMID:
16677861
18.
19.

The Ag85B protein of Mycobacterium tuberculosis may turn a protective immune response induced by Ag85B-DNA vaccine into a potent but non-protective Th1 immune response in mice.

Palma C, Iona E, Giannoni F, Pardini M, Brunori L, Orefici G, Fattorini L, Cassone A.

Cell Microbiol. 2007 Jun;9(6):1455-65. Epub 2007 Jan 22.

PMID:
17250590
20.

Live attenuated Salmonella vaccines displaying regulated delayed lysis and delayed antigen synthesis to confer protection against Mycobacterium tuberculosis.

Juárez-Rodríguez MD, Yang J, Kader R, Alamuri P, Curtiss R 3rd, Clark-Curtiss JE.

Infect Immun. 2012 Feb;80(2):815-31. doi: 10.1128/IAI.05526-11. Epub 2011 Dec 5.

Supplemental Content

Support Center